title: Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13).
abstract: We developed a real time reverse transcriptase polymerase chain reaction (RT-PCR) assay system for detecting the MOZ-CBP fusion transcript and used it to monitor minimal residual disease (MRD) status in a patient with therapy related acute myeloid leukemia (t-AML) harboring t(8;16)(p11;p13). Expression of the MOZ-CBP fusion transcript was determined by RT-PCR analysis of the patient's bone marrow at the time of diagnosis. Thereafter, real time RT-PCR was used to evaluate MRD levels throughout the entire course of treatment. The sensitivity of quantitative RT-PCR for the MOZ-CBP fusion transcript was 10(-5). Below this level, MRD was classified as negative. Real time RT-PCR of the bone marrow after induction therapy showed the reduction of MOZ-CBP transcript to approximately 10(-3) level when compared to the diagnostic sample. MRD was classified as negative (< 10(-5) compared with that in the bone marrow at diagnosis) after 5 courses of chemotherapy, a level that was maintained post-allo-hematopoietic stem cell transplantation. Real time RT-PCR of the MOZ-CBP transcript is a useful tool for assessing MRD status for a patient with therapy related acute myeloid leukemia who was initially predicted to have a poor prognosis.
authors.affiliation: Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fujiki
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Imamura
authors.forename: Akiyo
authors.initials: A
authors.lastname: Furutani
authors.forename: Waka
authors.initials: W
authors.lastname: Hatano
authors.forename: Daisuke
authors.initials: D
authors.lastname: Asai
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Hirashima
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Miyachi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Tamura
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Tomoko
authors.initials: T
authors.lastname: Iehara
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ishida
authors.forename: Takao
authors.initials: T
authors.lastname: Yoshihara
authors.forename: Hajime
authors.initials: H
authors.lastname: Hosoi
mesh_terms: D000293:Adolescent; D002885:Chromosomes, Human, Pair 16; D002898:Chromosomes, Human, Pair 8; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D018365:Neoplasm, Residual / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012333:RNA, Messenger / Q000032:analysis*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D014158:Transcription, Genetic; D014178:Translocation, Genetic
chemical_list: C470260:MOZ-CBP fusion protein, human; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger